19th Jul 2016 13:22
LONDON (Alliance News) - AstraZeneca PLC Tuesday said that its Qtern tablets for type 2 diabetes has been approved by the European Commission for all 28 European Union member countries.
It has also been approved for Iceland, Liechtenstein and Norway.
Qtern is indicated for adults with type 2 diabetes aged 18 or older, to help with the improvement of glycaemic control. The approval was based on data from three trials.
"Nearly half of all people with type 2 diabetes are unable to reach their treatment goal and so risk developing complications due to hyperglycaemia. Qtern is the first combination product of its kind approved in Europe and an important new treatment option to help patients reach their goals through powerful HbA1c reduction," said Elisabeth Bjork, head of cardiovascular and metabolic diseases, global medicines development at AstraZeneca.
Shares in AstraZeneca were up 0.2% at 4,534.00 pence Tuesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca